ABBV Jun 2022 70.000 call
| Previous close | 74.85 |
| Open | 74.85 |
| Bid | 89.85 |
| Ask | 90.75 |
| Strike | 70.00 |
| Expiry date | 2022-06-17 |
| Day's range | 74.85 - 74.85 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Simply Wall St.
What Kind Of Shareholders Hold The Majority In AbbVie Inc.'s (NYSE:ABBV) Shares?
If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share...
- PR Newswire
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced The Lancet published results from three pivotal Phase 3 clinical trials – U-ACHIEVE (induction), U-ACCOMPLISH and U-ACHIEVE (maintenance) – evaluating upadacitinib (RINVOQ®) in patients with moderately to severely active ulcerative colitis who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.
- PR Newswire
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
AbbVie (NYSE: ABBV) today announced The Lancet published results from three pivotal Phase 3 clinical trials – ADVANCE, MOTIVATE (induction studies) and FORTIFY (maintenance study) – evaluating risankizumab (SKYRIZI®) in patients with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.
